Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.54 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.37 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | CA3 | P07451 | 2/20 | 0.54 |
| ▸ | CA5A | P35218 | 2/20 | 0.54 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA4 | P22748 | 1/20 | 0.54 |
| ▸ | CA6 | P23280 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL67885 | 0.98 | ALDH1A1 (0.65) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| Trifluoroacetic Acid SCHEMBL17747121 | 0.91 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL29241548 | 0.86 | SMN1; SMN2 (0.71) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL10232648 | 0.85 | CA5B (0.77) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL29241679 | 0.85 | SMN1; SMN2 (0.75) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL8041559 | 0.85 | CA5B (0.77) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL3149189 | 0.84 | ALDH1A1 (0.74) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL28974271 | 0.83 | MEN1 (0.76) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL6490885 | 0.82 | ALDH1A1 (0.78) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL29241483 | 0.82 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116169357-A | Electrochemical device and electronic device | 东莞新能源科技有限公司 | 2023-05-26 | — | — | CN | claimed |
| US-12595318-B2 | — | — | 2026-04-07 | — | — | US | disclosed |
| US-12312574-B2 | Polymer-coated crosslinked alginate gel fiber | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2025-05-27 | — | — | US | disclosed |
| US-20240342340-A1 | MULTILAYER STRUCTURE USING CHEMICALLY CROSSLINKED ALGINIC ACID | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2024-10-17 | — | — | US | disclosed |
| US-20240174772-A1 | NOVEL CROSSLINKED ALGINIC ACID | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2024-05-30 | — | — | US | disclosed |
| US-20240174959-A1 | NOVEL POLYMER-COATED CROSSLINKED ALGINATE GEL FIBER | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2024-05-30 | — | — | US | disclosed |
| CN-118044519-A | Molecules having pesticidal utility, and intermediates, compositions and methods related thereto | 科迪华农业科技有限责任公司 | 2024-05-17 | — | — | CN | disclosed |
| EP-4361249-A1 | NOVEL POLYMER-COATED CROSSLINKED ALGINATE GEL FIBER | Mochida Pharmaceutical Co., Ltd. (JP) | 2024-05-01 | — | — | EP | disclosed |
| US-20240132854-A1 | NOVEL MULTILAYER POLYMER-COATED CROSSLINKED ALGINATE GEL FIBER | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2024-04-25 | — | — | US | disclosed |
| US-11932708-B2 | Crosslinked alginic acid | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2024-03-19 | — | — | US | disclosed |
| WO-2022145420-A1 | NOVEL MULTILAYER POLYMER-COATED CROSSLINKED ALGINATE GEL FIBER | 持田製薬株式会社 | 2022-07-07 | — | — | WO | disclosed |
| WO-2021125255-A1 | NOVEL CROSSLINKED ALGINIC ACID | 持田製薬株式会社 | 2021-06-24 | — | — | WO | disclosed |
| WO-2021125279-A1 | CHEMICALLY CROSSLINKED ALGINATE GEL FIBER | 持田製薬株式会社 | 2021-06-24 | — | — | WO | disclosed |
| EP-3808783-A1 | NOVEL CROSSLINKED ALGINIC ACID | Mochida Pharmaceutical Co., Ltd. (JP) | 2021-04-21 | — | — | EP | disclosed |
| US-20210095053-A1 | NOVEL CROSSLINKED ALGINIC ACID | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2021-04-01 | — | — | US | disclosed |
| CN-112236457-A | Novel cross-linked alginic acid | 持田制药株式会社 | 2021-01-15 | — | — | CN | disclosed |
| US-7311737-B2 | Secondary para-phenylenediamine compounds comprising N-alkylfluorine, dye compositions comprising them and processes of dyeing therewith | L'OREAL (FR) | 2007-12-25 | — | — | US | disclosed |
| US-20060021157-A1 | Secondary para-phenylenediamine compounds comprising N-alkylfluorine, dye compositions comprising them and processes of dyeing therewith | L'OREAL S.A. (FR) | 2006-02-02 | — | — | US | disclosed |
| US-20050043304-A1 | Novel amine derivative having human beta-tryptase inhibitory activity and drugs containing the same | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2005-02-24 | — | — | US | disclosed |
| EP-1445250-A1 | NOVEL AMINE DERIVATIVE HAVING HUMAN BETA-TRYPTASE INHIBITORY ACTIVITY AND DRUGS CONTAINING THE SAME | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060021157-A1 | Secondary para-phenylenediamine compounds comprising N-alkylfluorine, dye compositions comprising them and processes of dyeing therewith | KRT18, CDC73, FLNA | CA2 3278/4885HDAC6 1641/4885GLA 1820/4885 |
| US-20050043304-A1 | Novel amine derivative having human beta-tryptase inhibitory activity and drugs containing the same | TPSAB1, TPSB2, TPSD1 | CA2 694/4885HDAC6 2136/4885GLA 264/4885 |
| US-12595318-B2 | — | ALG1, ALG8, FUCA1 | CA2 398/4885HDAC6 1863/4885GLA 1512/4885 |
| US-20240132854-A1 | NOVEL MULTILAYER POLYMER-COATED CROSSLINKED ALGINATE GEL FIBER | IAPP, COG6, IL6 | CA2 1496/4885HDAC6 112/4885GLA 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.